ABC Arbitrage SA Boosts Position in Haleon PLC Sponsored ADR $HLN

ABC Arbitrage SA boosted its stake in Haleon PLC Sponsored ADR (NYSE:HLN) by 2.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,789,451 shares of the company’s stock after purchasing an additional 62,101 shares during the period. Haleon comprises 2.6% of ABC Arbitrage SA’s investment portfolio, making the stock its 10th largest position. ABC Arbitrage SA’s holdings in Haleon were worth $28,201,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC bought a new position in shares of Haleon in the fourth quarter worth approximately $187,000. AQR Capital Management LLC boosted its position in Haleon by 22.5% during the 1st quarter. AQR Capital Management LLC now owns 96,323 shares of the company’s stock valued at $991,000 after buying an additional 17,720 shares during the period. Focus Partners Wealth grew its holdings in Haleon by 7.6% in the 1st quarter. Focus Partners Wealth now owns 73,106 shares of the company’s stock worth $752,000 after acquiring an additional 5,178 shares during the last quarter. Geneos Wealth Management Inc. grew its holdings in Haleon by 33.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock worth $50,000 after acquiring an additional 1,203 shares during the last quarter. Finally, CW Advisors LLC increased its position in shares of Haleon by 11.6% in the second quarter. CW Advisors LLC now owns 25,075 shares of the company’s stock valued at $260,000 after acquiring an additional 2,601 shares during the period. Institutional investors own 6.67% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on HLN shares. Argus raised shares of Haleon to a “strong-buy” rating in a research note on Tuesday, March 17th. Wall Street Zen raised Haleon from a “hold” rating to a “buy” rating in a research report on Saturday, March 21st. HSBC upgraded Haleon from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 21st. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Haleon in a research report on Thursday, April 30th. Finally, Jefferies Financial Group restated a “buy” rating on shares of Haleon in a report on Tuesday, January 20th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $13.40.

Haleon Stock Performance

Shares of HLN opened at $8.98 on Tuesday. Haleon PLC Sponsored ADR has a one year low of $8.71 and a one year high of $11.42. The company has a 50-day simple moving average of $9.88 and a two-hundred day simple moving average of $9.98. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.92 and a quick ratio of 0.71. The firm has a market capitalization of $39.93 billion, a PE ratio of 23.01, a price-to-earnings-growth ratio of 2.07 and a beta of 0.15.

Haleon (NYSE:HLN) last announced its earnings results on Saturday, February 14th. The company reported $6.32 earnings per share (EPS) for the quarter. The firm had revenue of $3.65 billion during the quarter. On average, analysts anticipate that Haleon PLC Sponsored ADR will post 0.56 EPS for the current fiscal year.

Haleon Announces Dividend

The company also recently disclosed a dividend, which will be paid on Thursday, May 14th. Shareholders of record on Friday, April 10th will be issued a $0.1307 dividend. The ex-dividend date is Friday, April 10th. This represents a yield of 266.0%. Haleon’s dividend payout ratio is 61.54%.

Haleon Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.